Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + intensity modulated radiation therapy
- Development stage
- Unknown
- Lead developer
- NRG Oncology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen consists of the chemotherapy agents gemcitabine and cisplatin administered concurrently with image-guided intensity modulated radiation therapy (IG-IMRT). Developed and studied by the University of California, San Diego, specifically for the treatment of locally advanced cervical carcinoma, the regimen aims to utilize the radiosensitizing properties of both gemcitabine and cisplatin. Gemcitabine is a nucleoside analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and competing for incorporation into DNA, while cisplatin is a platinum-based agent that creates inter- and intra-strand DNA cross-links. The use of IMRT is intended to reduce gastrointestinal and hematologic toxicity compared to conventional radiation, potentially allowing for higher doses of concurrent chemotherapy to be delivered safely.
- Other names
- gemcitabine + cisplatin + IMRTgemcitabine + cisplatin + intensity modulated radiation therapy
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + cisplatin + intensity modulated radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + intensity modulated radiation therapy.